Mylan said the products mark the first generic versions of Benicar and Benicar HCT tablets from Daiichi Sankyo.
Mylan’s olmesartan medoxomil generic comes in strengths of 5 mg, 20 mg and 40 mg, while the olmesartan medoxomil/hydrochlorothiazide product is available in dosages of 20 mg/12.5 mg, 40 mg/12.5 mg and 40 mg/25 mg.
Olmesartan medoxomil tablets are indicated for the treatment of hypertension, or along with other antihypertensive agents to lower blood pressure. Olmesartan medoxomil/hydrochlorothiazide tablets are also used to reduce blood pressure but aren’t indicated for the initial therapy of hypertension.
For the 12 months ended Aug. 31, olmesartan medoxomil tablets (5 mg, 20 mg and 40 mg) totaled U.S. sales of approximately $1 billion, according to IMS Health data reported by Mylan. During the same time frame, olmesartan medoxomil/hydrochlorothiazide tablets (20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg) had U.S. sales of about $805 million.